 |
Products |  |
Diseases | | Products |
|
Trials |  |
News |  |
| «12...910111213141516171819...2223» |
- || Halaven (eribulin mesylate) / Eisai
New P2 trial, Metastases: ERASING: Eribulin in Advanced Solitary Fibrous Tumor (clinicaltrials.gov) - Feb 15, 2019
P2, N=16, Not yet recruiting, Sponsor: Italian Sarcoma Group
- | Halaven (eribulin mesylate) / Eisai
Trial completion date, Trial primary completion date: Treatment of Brain Metastases From Breast Cancer With Eribulin Mesylate (clinicaltrials.gov) - Feb 11, 2019
P2, N=9, Active, not recruiting, Sponsor: Case Comprehensive Cancer Center
Trial completion date: Oct 2019 --> Jul 2020 | Trial primary completion date: Jan 2018 --> Jul 2018
- | Halaven (eribulin mesylate) / Eisai, Cotellic (cobimetinib) / Exelixis, Roche, Tecentriq (atezolizumab) / Roche
Trial completion date, PD(L)-1 Biomarker, Metastases: Atezolizumab, Cobimetinib, and Eribulin in Treating Patients With Chemotherapy Resistant Metastatic Inflammatory Breast Cancer (clinicaltrials.gov) - Feb 8, 2019
P2, N=33, Recruiting, Sponsor: M.D. Anderson Cancer Center
Trial completion date: Oct 2019 --> Jul 2020 | Trial primary completion date: Jan 2018 --> Jul 2018 Trial completion date: Aug 2021 --> Aug 2020
- | Keytruda (pembrolizumab) / Merck (MSD), Halaven (eribulin mesylate) / Eisai
Enrollment closed: A Randomized Phase II Study Of Eribulin Mesylate With or Without Pembrolizumab For Metastatic Hormone Receptor Positive Breast Cancer (clinicaltrials.gov) - Feb 8, 2019
P2, N=88, Active, not recruiting, Sponsor: Dana-Farber Cancer Institute
Trial completion date: Aug 2021 --> Aug 2020 Recruiting --> Active, not recruiting
- | Halaven (eribulin mesylate) / Eisai
Trial completion, Trial completion date, Trial primary completion date: Eribulin in HER2 Negative Metastatic BrCa (clinicaltrials.gov) - Feb 6, 2019
P2, N=83, Completed, Sponsor: Dana-Farber Cancer Institute
Recruiting --> Active, not recruiting Active, not recruiting --> Completed | Trial completion date: Jul 2018 --> May 2016 | Trial primary completion date: Jun 2017 --> May 2016
- | Halaven (eribulin mesylate) / Eisai
Trial completion date, Trial primary completion date: EMBRACE: Eribulin Mesylate or Paclitaxel as First- or Second-Line Therapy in Treating Patients With Recurrent Stage IIIC-IV Breast Cancer (clinicaltrials.gov) - Feb 6, 2019
P3, N=910, Active, not recruiting, Sponsor: Academic and Community Cancer Research United
Active, not recruiting --> Completed | Trial completion date: Jul 2018 --> May 2016 | Trial primary completion date: Jun 2017 --> May 2016 Trial completion date: Jun 2019 --> Jun 2020 | Trial primary completion date: Jun 2018 --> Jun 2019
- ||| Halaven (eribulin mesylate) / Eisai
Enrollment change, Trial primary completion date: Study of Eribulin Mesylate in Combination With PEGylated Recombinant Human Hyaluronidase (PEGPH20) Versus Eribulin Mesylate Alone in Subjects With Human Epidermal Growth Factor Receptor 2 (HER2)-Negative, High-Hyaluronan (HA) Metastatic Breast Cancer (MBC) (clinicaltrials.gov) - Feb 5, 2019
P1b/2, N=14, Active, not recruiting, Sponsor: Eisai Inc.
Trial completion date: Jun 2019 --> Jun 2020 | Trial primary completion date: Jun 2018 --> Jun 2019 N=114 --> 14 | Trial primary completion date: May 2019 --> Mar 2018
- ||| Halaven (eribulin mesylate) / Eisai
Trial completion: A Study to Investigate the Efficacy and Safety of Eribulin in Korean Breast Cancer Participants (clinicaltrials.gov) - Jan 25, 2019
P=N/A, N=340, Completed, Sponsor: Eisai Korea Inc.
N=114 --> 14 | Trial primary completion date: May 2019 --> Mar 2018 Recruiting --> Completed
- | Keytruda (pembrolizumab) / Merck (MSD)
Trial primary completion date, Metastases: Study of Single Agent Pembrolizumab (MK-3475) Versus Single Agent Chemotherapy for Metastatic Triple Negative Breast Cancer (MK-3475-119/KEYNOTE-119) (clinicaltrials.gov) - Jan 24, 2019
P3, N=600, Active, not recruiting, Sponsor: Merck Sharp & Dohme Corp.
Recruiting --> Completed Trial primary completion date: Dec 2018 --> Apr 2019
- | Halaven (eribulin mesylate) / Eisai
New P2 trial, Combination therapy, Metastases: A Study of Eribulin With Gemcitabine in Patients With Advanced Liposarcoma or Leiomyosarcoma (clinicaltrials.gov) - Jan 21, 2019
P2, N=37, Recruiting, Sponsor: Yonsei University
- | Halaven (eribulin mesylate) / Eisai
Trial primary completion date: BOLD 113: This is a Phase 1 Study of Eribulin Mesylate in Pediatric Participants With Recurrent or Refractory Solid Tumors (Excluding [Central Nervous System] CNS), Including Lymphomas (clinicaltrials.gov) - Jan 15, 2019
P1, N=23, Completed, Sponsor: Eisai Inc.
Trial primary completion date: Dec 2018 --> Apr 2019 Trial primary completion date: Apr 2015 --> Jan 2016
- |||| paclitaxel trevatide (ANG1005) / Angiochem
Trial completion date, Trial initiation date, Trial primary completion date: ANGLeD: ANG1005 in Leptomeningeal Disease From Breast Cancer (clinicaltrials.gov) - Jan 9, 2019
P3, N=150, Not yet recruiting, Sponsor: Angiochem Inc
Trial primary completion date: Apr 2015 --> Jan 2016 Trial completion date: Jan 2021 --> May 2021 | Initiation date: Dec 2018 --> Apr 2019 | Trial primary completion date: Dec 2020 --> Apr 2021
- | Halaven (eribulin mesylate) / Eisai
Trial completion date, Combination therapy, Metastases: Eribulin Mesylate in Combination With Intermittent Erlotinib in Patients With Previously Treated, Advanced Non-Small Cell Lung Cancer (clinicaltrials.gov) - Jan 8, 2019
P2, N=123, Completed, Sponsor: Eisai Inc.
Trial completion date: Jan 2021 --> May 2021 | Initiation date: Dec 2018 --> Apr 2019 | Trial primary completion date: Dec 2020 --> Apr 2021 Trial completion date: Feb 2018 --> Jan 2017
- | Halaven (eribulin mesylate) / Eisai
New P2 trial, Monotherapy: REVERT: Trial With Eribulin or Eribulin+ Endocrine Therapy in Locally-recurrent or Metastatic Breast Cancer Patients (clinicaltrials.gov) - Jan 7, 2019
P2, N=60, Not yet recruiting, Sponsor: MedSIR
- | bintrafusp alfa (M7824) / EMD Serono, Halaven (eribulin mesylate) / Eisai
New P1 trial, Metastases: M7824 and Eribulin Mesylate in Treating Patients With Metastatic Triple Negative Breast Cancer (clinicaltrials.gov) - Jan 3, 2019
P1, N=20, Recruiting, Sponsor: M.D. Anderson Cancer Center
- | Halaven (eribulin mesylate) / Eisai
Trial primary completion date: A Study of Eribulin in Combination With Oral Irinotecan for Adolescent and Young Adult Patients With Relapsed or Refractory Solid Tumors (clinicaltrials.gov) - Dec 28, 2018
P1/2, N=21, Recruiting, Sponsor: University of Colorado, Denver
Trial completion date: Feb 2018 --> Jan 2017 Trial primary completion date: Oct 2018 --> Feb 2019
- |||||||||| balixafortide (POL 6326) / Spexis
New P3 trial, Combination therapy, Metastases: FORTRESS: Pivotal Study in HER2 Negative, Locally Recurrent or Metastatic Breast Cancer (clinicaltrials.gov) - Dec 23, 2018
P3, N=384, Not yet recruiting, Sponsor: Polyphor Ltd.
- |||||| Enhertu (fam-trastuzumab deruxtecan-nxki) / Daiichi Sankyo, AstraZeneca
Enrollment open: Trastuzumab Deruxtecan (DS-8201a) Versus Investigator's Choice for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed [DESTINY-Breast04] (clinicaltrials.gov) - Dec 21, 2018
P3, N=540, Recruiting, Sponsor: Daiichi Sankyo, Inc.
Trial primary completion date: Oct 2018 --> Feb 2019 Not yet recruiting --> Recruiting
- ||| Halaven (eribulin mesylate) / Eisai
Trial completion, Trial completion date, Trial primary completion date: Halaven Post-Marketing Surveillance (PMS) (clinicaltrials.gov) - Dec 20, 2018
P=N/A, N=3000, Completed, Sponsor: Eisai Korea Inc.
Not yet recruiting --> Recruiting Active, not recruiting --> Completed | Trial completion date: Aug 2018 --> Nov 2018 | Trial primary completion date: Aug 2018 --> Nov 2018
- | Xpovio (selinexor) / Karyopharm
Enrollment change, IO biomarker: NCI-2015-00693: Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination with Multiple Standard Chemotherapy or Immunotherapy Agents in Patients with Advanced Malignancies (clinicaltrials.gov) - Dec 17, 2018
P1, N=247, Recruiting, Sponsor: M.D. Anderson Cancer Center
Active, not recruiting --> Completed | Trial completion date: Aug 2018 --> Nov 2018 | Trial primary completion date: Aug 2018 --> Nov 2018 N=588 --> 247
- | Halaven (eribulin mesylate) / Eisai
Trial primary completion date, Metastases: Eribulin Mesylate in Treating Patients With Locally Advanced or Metastatic Cancer of the Urothelium and Kidney Dysfunction (clinicaltrials.gov) - Dec 11, 2018
P1/2, N=132, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
N=588 --> 247 Trial primary completion date: Dec 2018 --> Dec 2019
- ||||| Trodelvy (sacituzumab govitecan-hziy) / Gilead
Enrollment change, Metastases: ASCENT: Trial of Sacituzumab Govitecan in Participants With Refractory/Relapsed Metastatic Triple-Negative Breast Cancer (TNBC) (clinicaltrials.gov) - Dec 11, 2018
P3, N=488, Recruiting, Sponsor: Immunomedics, Inc.
Trial primary completion date: Dec 2018 --> Dec 2019 N=328 --> 488
- | Halaven (eribulin mesylate) / Eisai
New trial, Metastases: Loreline Study: Characterization of Long Responders Under Eribuline (clinicaltrials.gov) - Dec 11, 2018
P, N=200, Not yet recruiting, Sponsor: Centre Jean Perrin
- ||| Halaven (eribulin mesylate) / Eisai, Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Trial completion date, Trial termination, Trial primary completion date: Phase II Study of Eribulin Mesylate, Trastuzumab, and Pertuzumab in Women With Metastatic, Unresectable Locally Advanced, or Locally Recurrent HER2-Positive Breast Cancer (clinicaltrials.gov) - Dec 5, 2018
P2, N=32, Terminated, Sponsor: Dana-Farber Cancer Institute
N=328 --> 488 Trial completion date: Mar 2020 --> Dec 2016 | Active, not recruiting --> Terminated | Trial primary completion date: May 2017 --> Dec 2016; The study terminated early due to weak accrual.
- || Halaven (eribulin mesylate) / Eisai
Enrollment closed: ENHANCE-1: Study to Evaluate the Efficacy and Safety of Eribulin Mesylate in Combination With Pembrolizumab in Participants With Metastatic Triple-Negative Breast Cancer (mTNBC) (clinicaltrials.gov) - Dec 5, 2018
P1b/2, N=167, Active, not recruiting, Sponsor: Eisai Inc.
Trial completion date: Mar 2020 --> Dec 2016 | Active, not recruiting --> Terminated | Trial primary completion date: May 2017 --> Dec 2016; The study terminated early due to weak accrual. Recruiting --> Active, not recruiting
- | Halaven (eribulin mesylate) / Eisai
Trial primary completion date, Metastases: Study to Evaluate the Efficacy and Safety of Eribulin Mesylate Administered Biweekly (Q2W) for Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Metastatic Breast Cancer (clinicaltrials.gov) - Nov 15, 2018
P2, N=58, Completed, Sponsor: Eisai Inc.
Recruiting --> Active, not recruiting Trial primary completion date: Sep 2017 --> Dec 2016
- | Halaven (eribulin mesylate) / Eisai
Trial primary completion date, Metastases: Eribulin Mesylate in Treating Patients With Previously Treated Metastatic Breast Cancer (clinicaltrials.gov) - Nov 13, 2018
P2, N=72, Active, not recruiting, Sponsor: University of Washington
Trial primary completion date: Sep 2017 --> Dec 2016 Trial primary completion date: Aug 2018 --> May 2019
- | Enhertu (fam-trastuzumab deruxtecan-nxki) / Daiichi Sankyo, AstraZeneca
New P3 trial: Trastuzumab Deruxtecan (DS-8201a) Versus Investigator's Choice for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed [DESTINY-Breast04] (clinicaltrials.gov) - Nov 7, 2018
P3, N=540, Not yet recruiting, Sponsor: Daiichi Sankyo, Inc.
- | bimiralisib (PQR309) / Torqur
Trial completion, Enrollment change: PQR309 and Eribulin in Metastatic HER2 Negative and Triple-negative Breast Cancer (PIQHASSO) (clinicaltrials.gov) - Oct 19, 2018
P1/2, N=41, Completed, Sponsor: PIQUR Therapeutics AG
Trial primary completion date: Aug 2018 --> May 2019 Recruiting --> Completed | N=60 --> 41
- |||||| Margenza (margetuximab-cmkb) / MacroGenics
Enrollment open: SOPHIA: Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of HER2+ Metastatic Breast Cancer (clinicaltrials.gov) - Oct 18, 2018
P3, N=530, Recruiting, Sponsor: MacroGenics
Recruiting --> Completed | N=60 --> 41 Active, not recruiting --> Recruiting
- | Ixempra (ixabepilone) - Otsuka, R / Pharm, Halaven (eribulin mesylate) / Eisai
Biomarker, Trial suspension, Biopsy: Pharmacodynamic Biomarkers of Standard Anti-microtubule Drugs as Assessed by Early Tumor Biopsy (clinicaltrials.gov) - Oct 16, 2018
P=N/A, N=35, Suspended, Sponsor: University of Wisconsin, Madison
Active, not recruiting --> Recruiting Recruiting --> Suspended
- ||||| Margenza (margetuximab-cmkb) / MacroGenics
Enrollment closed: SOPHIA: Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of HER2+ Metastatic Breast Cancer (clinicaltrials.gov) - Oct 10, 2018
P3, N=530, Active, not recruiting, Sponsor: MacroGenics
Recruiting --> Suspended Recruiting --> Active, not recruiting
- | Halaven (eribulin mesylate) / Eisai
Trial completion date, Trial primary completion date, Metastases: Neuropharmacokinetics of Eribulin Mesylate in Treating Patients With Primary or Metastatic Brain Tumors (clinicaltrials.gov) - Oct 9, 2018
P1, N=8, Active, not recruiting, Sponsor: City of Hope Medical Center
Recruiting --> Active, not recruiting Trial completion date: Sep 2018 --> Sep 2019 | Trial primary completion date: Sep 2018 --> Sep 2019
- | Halaven (eribulin mesylate) / Eisai
Trial completion date, Combination therapy, Metastases: Eribulin Mesylate in Combination With Intermittent Erlotinib in Patients With Previously Treated, Advanced Non-Small Cell Lung Cancer (clinicaltrials.gov) - Oct 3, 2018
P2, N=123, Completed, Sponsor: Eisai Inc.
Trial completion date: Sep 2018 --> Sep 2019 | Trial primary completion date: Sep 2018 --> Sep 2019 Trial completion date: Jan 2017 --> Feb 2018
- | Halaven (eribulin mesylate) / Eisai
Trial completion, Combination therapy, Surgery, Metastases: Eribulin Mesylate and Gemcitabine Hydrochloride in Treating Patients With Metastatic Solid Tumors or Solid Tumors That Cannot be Removed by Surgery (clinicaltrials.gov) - Oct 3, 2018
P1, N=45, Completed, Sponsor: National Cancer Institute (NCI)
Trial completion date: Jan 2017 --> Feb 2018 Active, not recruiting --> Completed
- || Trial completion date, Trial primary completion date, PARP Biomarker, PD(L)-1 Biomarker, IO biomarker: SAFIR02_Breast - Efficacy of Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Breast Cancer (clinicaltrials.gov) - Oct 1, 2018
P2, N=1460, Recruiting, Sponsor: UNICANCER
Active, not recruiting --> Completed Trial completion date: Jun 2021 --> Dec 2022 | Trial primary completion date: Jun 2019 --> Dec 2021
- | Halaven (eribulin mesylate) / Eisai
Trial completion: Dose Dense Doxorubucin and Cyclophosphamide Followed by Eribulin Mesylate for the Adjuvant Treatment of Early Stage Breast Cancer (clinicaltrials.gov) - Sep 26, 2018
P2, N=81, Completed, Sponsor: Eisai Inc.
Trial completion date: Jun 2021 --> Dec 2022 | Trial primary completion date: Jun 2019 --> Dec 2021 Active, not recruiting --> Completed
- | Halaven (eribulin mesylate) / Eisai
Enrollment change, Trial completion date, Trial primary completion date, Metastases: A Study to Evaluate Safety, Tolerability and Efficacy of Eribulin Mesylate in Treating Adult Females With Locally Advanced or Metastatic Breast Cancer (clinicaltrials.gov) - Sep 26, 2018
P4, N=83, Recruiting, Sponsor: Eisai Inc.
Active, not recruiting --> Completed N=200 --> 83 | Trial completion date: Aug 2018 --> Jun 2019 | Trial primary completion date: Aug 2018 --> Feb 2019
- | Halaven (eribulin mesylate) / Eisai
Enrollment change, Trial termination: ALERT: A Phase II Study of Alternating Eribulin and Hormonal Therapy in Pre-treated ER+ve Breast Cancer. (clinicaltrials.gov) - Sep 20, 2018
P2, N=8, Terminated, Sponsor: Imperial College London
N=200 --> 83 | Trial completion date: Aug 2018 --> Jun 2019 | Trial primary completion date: Aug 2018 --> Feb 2019 N=12 --> 8 | Recruiting --> Terminated; Slow patient recruitment
- | Halaven (eribulin mesylate) / Eisai
Trial primary completion date: SAKK 25/14: Eribulin as 1st Line Treatment in Elderly Patients With Advanced Breast Cancer (clinicaltrials.gov) - Sep 18, 2018
P2, N=77, Recruiting, Sponsor: Swiss Group for Clinical Cancer Research
N=12 --> 8 | Recruiting --> Terminated; Slow patient recruitment Trial primary completion date: Oct 2018 --> Jun 2019
- | balixafortide (POL 6326) / Spexis
Trial completion, Trial completion date, Trial primary completion date: Dose Escalation of POL6326 in Combination With Eribulin in Patients With Metastatic Breast Cancer (clinicaltrials.gov) - Sep 14, 2018
P1, N=54, Completed, Sponsor: Polyphor Ltd.
Trial primary completion date: Oct 2018 --> Jun 2019 Active, not recruiting --> Completed | Trial completion date: Jun 2017 --> Aug 2018 | Trial primary completion date: Apr 2017 --> Aug 2018
- | Halaven (eribulin mesylate) / Eisai
Trial completion date, Trial primary completion date, Metastases: Eribulin Mesylate and Everolimus in Treating Patients With Triple-Negative Metastatic Breast Cancer (clinicaltrials.gov) - Sep 10, 2018
P1, N=45, Active, not recruiting, Sponsor: City of Hope Medical Center
Active, not recruiting --> Completed | Trial completion date: Jun 2017 --> Aug 2018 | Trial primary completion date: Apr 2017 --> Aug 2018 Trial completion date: Dec 2018 --> Dec 2019 | Trial primary completion date: Dec 2018 --> Dec 2019
- | Halaven (eribulin mesylate) / Eisai
Trial completion date, Trial initiation date, Trial primary completion date, Combination therapy: Study Evaluating the Safety and Efficacy of Eribulin Mesilate in Combination With Irinotecan Hydrochloride in Children With Refractory or Recurrent Solid Tumors (clinicaltrials.gov) - Sep 10, 2018
P1/2, N=111, Recruiting, Sponsor: Eisai Inc.
Trial completion date: Dec 2018 --> Dec 2019 | Trial primary completion date: Dec 2018 --> Dec 2019 Trial completion date: Oct 2020 --> Jun 2021 | Initiation date: Jul 2017 --> Feb 2018 | Trial primary completion date: Jun 2020 --> Jun 2021
- || Halaven (eribulin mesylate) / Eisai
Trial completion date, Trial primary completion date: Study of Eribulin Mesylate in Combination With PEGylated Recombinant Human Hyaluronidase (PEGPH20) Versus Eribulin Mesylate Alone in Subjects With Human Epidermal Growth Factor Receptor 2 (HER2)-Negative, High-Hyaluronan (HA) Metastatic Breast Cancer (MBC) (clinicaltrials.gov) - Sep 7, 2018
P1b/2, N=114, Active, not recruiting, Sponsor: Eisai Inc.
Trial completion date: Oct 2020 --> Jun 2021 | Initiation date: Jul 2017 --> Feb 2018 | Trial primary completion date: Jun 2020 --> Jun 2021 Trial completion date: Dec 2018 --> May 2019 | Trial primary completion date: Aug 2018 --> May 2019
- | Halaven (eribulin mesylate) / Eisai
Enrollment closed: HAL03T: A Study on Safety and Efficacy in Patients With Soft Tissue Sarcomas (clinicaltrials.gov) - Sep 7, 2018
P=N/A, N=160, Active, not recruiting, Sponsor: Eisai Co., Ltd.
Trial completion date: Dec 2018 --> May 2019 | Trial primary completion date: Aug 2018 --> May 2019 Recruiting --> Active, not recruiting
- | Halaven (eribulin mesylate) / Eisai
Trial completion date: ENHANCE-1: Study to Evaluate the Efficacy and Safety of Eribulin Mesylate in Combination With Pembrolizumab in Participants With Metastatic Triple-Negative Breast Cancer (mTNBC) (clinicaltrials.gov) - Sep 6, 2018
P1b/2, N=147, Recruiting, Sponsor: Eisai Inc.
Recruiting --> Active, not recruiting Trial completion date: Mar 2020 --> Jul 2019
- | Halaven (eribulin mesylate) / Eisai
Trial completion, Trial completion date: Eribulin Versus Vinorelbine in Subjects With Locally Recurrent or Metastatic Breast Cancer Previously Treated With Anthracyclines and Taxanes (clinicaltrials.gov) - Aug 28, 2018
P3, N=530, Completed, Sponsor: Eisai Co., Ltd.
Trial completion date: Mar 2020 --> Jul 2019 Active, not recruiting --> Completed | Trial completion date: Mar 2018 --> Jun 2018
- ||||| Onzeald (etirinotecan pegol) / Nektar Therap
Enrollment change, Trial completion date, Trial primary completion date, Metastases: ATTAIN: A Study of Etirinotecan Pegol (NKTR-102) Versus Treatment of Physician's Choice (TPC) in Patients With Metastatic Breast Cancer Who Have Stable Brain Metastases and Have Been Previously Treated With an Anthracycline, a Taxane, and Capecitabine (clinicaltrials.gov) - Aug 28, 2018
P3, N=220, Recruiting, Sponsor: Nektar Therapeutics
Active, not recruiting --> Completed | Trial completion date: Mar 2018 --> Jun 2018 N=350 --> 220 | Trial completion date: Feb 2020 --> Mar 2021 | Trial primary completion date: Aug 2019 --> Jul 2020
- | Halaven (eribulin mesylate) / Eisai
Enrollment closed, Trial completion date, Trial primary completion date, Metastases: PAINTER: Polymorphism And INcidence of Toxicity in ERibulin Treatment (clinicaltrials.gov) - Aug 23, 2018
P4, N=200, Active, not recruiting, Sponsor: Oncologia Medica dell'Ospedale Fatebenefratelli
N=350 --> 220 | Trial completion date: Feb 2020 --> Mar 2021 | Trial primary completion date: Aug 2019 --> Jul 2020 Recruiting --> Active, not recruiting | Trial completion date: Dec 2017 --> Dec 2018 | Trial primary completion date: Dec 2017 --> Dec 2018
- | Halaven (eribulin mesylate) / Eisai
Trial completion date: HAL03T: A Study on Safety and Efficacy in Patients With Soft Tissue Sarcomas (clinicaltrials.gov) - Aug 23, 2018
P=N/A, N=160, Recruiting, Sponsor: Eisai Co., Ltd.
Recruiting --> Active, not recruiting | Trial completion date: Dec 2017 --> Dec 2018 | Trial primary completion date: Dec 2017 --> Dec 2018 Trial completion date: Nov 2019 --> Nov 2018